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Abstract:  
Inactivation of the VHL tumor suppressor gene is the signature initiating event in clear cell renal 
cell carcinoma (ccRCC), the most common form of kidney cancer, and causes the accumulation 
of hypoxia-inducible factor 2a (HIF2a). HIF2a inhibitors are effective in some ccRCC cases, but 
both de novo and acquired resistance have been observed in the laboratory and in the clinic. 
Here we identified synthetic lethality between decreased activity of cyclin-dependent kinases 4 
and 6 (CDK4/6) and VHL inactivation in two species (human and Drosophila) and across 
diverse human ccRCC cell lines in culture and in xenografts. Although HIF2a transcriptionally 
induced the CDK4/6 partner cyclin D1, HIF2a was not required for the increased CDK4/6 
requirement of VHL-/- ccRCC cells.  Accordingly, the antiproliferative effects of CDK4/6 inhibition 
were synergistic with HIF2a inhibition in HIF2a-dependent VHL-/- ccRCC cells and not 
antagonistic in HIF2a-independent cells. These findings support testing CDK4/6 inhibitors as 
treatments for ccRCC, alone and in combination with HIF2a inhibitors. 
 
  
Introduction 
 
Over 400,000 patients are diagnosed with kidney cancer annually, making it one of the 
ten most common forms of cancer in the developed world (1). In the United States, over 14,500 
patients die of kidney cancer each year (2). The most common type of kidney cancer is clear 
cell renal cell carcinoma (ccRCC), which accounts for >70% of all kidney cancer cases (3). 
The von Hippel-Lindau tumor suppressor gene (VHL) is mutionally inactivated or 
hypermethylated in nearly 90% of ccRCCs, leading to the synthesis of a dysfunctional pVHL (or 
no pVHL at all) (4). pVHL is a part of an E3 ubiquitin ligase that targets the transcription factor 
hypoxia-inducible factor 2a (HIF2a) for proteasomal degradation. In renal cells lacking pVHL, 
HIF2a accumulates and acts as an oncogenic driver by transcriptionally activating proliferative 
and angiogenic genes, such as those encoding cyclin D1 (CCND1) and vascular endothelial 
growth factor (VEGF), respectively.  
Localized ccRCC can often be managed with a partial or radical nephrectomy. Patients 
who recur after surgery, or who present with advanced or metastatic disease, are typically 
treated with VEGF inhibitors or immune checkpoint inhibitors as first-line therapies. Although 
these treatments can cause disease control in a substantial proportion of patients, few (if any) 
ccRCC patients are cured with these agents. Patients who do not respond to these therapies 
are sometimes treated with inhibitors of mammalian target of rapamycin (mTOR), which are also 
palliative and not curative in this setting. Small molecules that directly target HIF2a are 
promising for the treatment of pVHL-defective ccRCCs (5-7). However, the response of pVHL-
defective ccRCCs to HIF2a inhibitors appears to be heterogeneous based on preclinical and 
early clinical data (5-7). Therefore new therapeutic targets are needed in ccRCC. Ideally, drugs 
against these targets would be active as single agents and would also lend themselves to 
combinations with existing agents as a means of decreasing the likelihood of acquired and de 
novo resistance.  
One approach for developing new therapy options in ccRCC would be to identify targets 
that have synthetic lethal relationships with VHL loss. Synthetic lethality describes a relationship 
between two genes where the loss of either gene alone is tolerated, but the concurrent loss of 
both genes is lethal. Applying synthetic lethality to identify therapeutic targets is particularly 
attractive for cancer as it leverages mutations that are cancer-specific, thereby creating a 
potential therapeutic window between cancer cells and normal host cells. Genes or proteins 
whose inactivation is selectively lethal in the context of VHL inactivation would theoretically be 
ideal candidates for the therapy in ccRCC. 
A few genes have been reported to be synthetically lethal with VHL loss (8-11). A 
challenge is to ensure that synthetic lethal relationships are robust across models and not 
peculiar to, for example, an extremely narrow set of cell lines that are not truly representative of 
the genotype of interest. In an earlier pilot study, we identified CDK6 as being synthetic lethal 
with VHL in the context of two different ccRCC lines (12). Here, we performed synthetic lethal 
screens in isogenic Drosophila cells using RNA interference (RNAi) and isogenic human ccRCC 
cells using a focused chemical library. These screens reidentified inactivation of CDK4/6 as 
synthetic lethal with loss of VHL, suggesting that this interaction is highly robust. We found that 
increased HIF2a activity was not necessary for this synthetic lethal interaction. Inhibiting 
CDK4/6 suppressed the proliferation of pVHL-defective ccRCCs both ex vivo and in vivo, 
including pVHL-defective ccRCCs that are HIF2a-independent. Moreover, CDK4/6 inhibitors 
enhanced the activity of a HIF2a inhibitor in HIF2a-dependent ccRCCs. Therefore, CDK4/6 
inhibition is an attractive new avenue for treating pVHL-defective ccRCCs. 
Results  
 
Loss of CDK4/6 activity selectively inhibits the fitness of VHL-deficient cells relative to VHL-
proficient cells in multiple species 
We screened for genes that are synthetic lethal with VHL inactivation in Drosophila 
melanogaster S2R+ cells and in human ccRCC cells, reasoning that a synthetic lethal 
relationship that was true in both of these species would likely represent a fundamental 
dependency that would be robust enough to withstand many differences among human cell 
lines and variability between patients. 
For the Drosophila screen, we first used CRISPR/Cas9-based gene editing to inactivate 
vhl, the Drosophila ortholog of the human VHL gene, in S2R+ cells. Using single-cell cloning, 
we generated an S2R+ derivative that had a vhl frameshift mutation (hereafter referred to as 
vhl-null S2R+ cells) and confirmed that this derivative accumulated high amounts of hypoxia-
inducible mRNAs (such as LDH and CG11652) driven by sima, which is the Drosophila ortholog 
of the human genes encoding HIF1a and HIF2a (Fig. 1A). 
Next, we seeded the wild-type and vhl-null S2R+ cells into separate 384-well plates, with 
each well containing a unique double-stranded RNA (dsRNA) from a focused Drosophila dsRNA 
library targeting 448 Drosophila genes (with ~3 dsRNAs/gene) that are orthologous to 691 
human genes (due to cases where a single ancestral ortholog in Drosophila has multiple 
paralogs in human) that encode protein targets of FDA-approved drugs. In addition, the library 
contained dsRNAs targeting thread as a pan-lethal control and dsRNAs against GFP and LacZ 
as negative controls. Cells were incubated with dsRNAs for 4 days prior to assessment of cell 
number using CellTiter-Glo in 3 biological replicates. The data for the wild-type cells was pooled 
with data from 6 earlier replicates done with the same library. Z-scores were calculated for the 
effects of individual dsRNAs and were used to identify dsRNAs that inhibited viability in the vhl-
null cells but not in the wild-type cells (Fig. 1B-D). The Drosophila gene cdk4, which is the 
ancestral ortholog of the human genes encoding CDK4 and CDK6, was the top-scoring gene 
fulfilling this criterion. The full dataset is available at www.flyrnai.org/screensummary (and data 
file S1). 
For the screen in human cells, we made 786-O and UMRC-2 human VHL-/- ccRCC cells 
expressing both VHL and GFP (hereafter called VHL cells) or GFP alone (hereafter called EV 
cells) using bicistronic lentiviruses that did or did not contain a VHL cDNA, respectively. We 
confirmed that reintroduction of wild-type pVHL suppressed HIF2a protein abundance (Fig. 2A). 
Next the VHL and EV cells were seeded into separate 384-well plates, with each well containing 
a unique chemical from a library of ~400 annotated chemicals with known anticancer activity. 
These chemicals targeted proteins encoded by 227 unique genes (some chemicals had multiple 
or overlapping targets and some chemicals had unknown targets). Each chemical was tested at 
10 concentrations from 1 nM to 20 µM in 2 biological replicates. Cells were incubated with 
compounds for 48 hours, after which the number of GFP-positive objects per well was assessed 
as a proxy for cell number. Z-scores were calculated for the effects of individual drugs using 
DMSO as a negative control and epothilone B as a pan-lethal control (Fig. 2B-C and data file 
S2). We identified a total of 63 compounds that inhibited the growth of VHL-defective 786-O and 
UMRC-2 cells more significantly than their VHL-reconstituted counterparts; two of these 
compounds (flavopiridol and AT7519) targeted proteins encoded by genes for which the 
Drosophila ortholog scored in our Drosophila screen (CDK2, CDK4, and CDK6) (Fig. 2D and 
data file S3). CDK4/6 was the only target that scored among the top 10 hits in both screens and 
was therefore pursued further. 
 
Pharmacological inhibition of CDK4/6 preferentially suppresses the fitness of VHL-defective 
ccRCC cells 
 We next performed low throughput experiments to validate the synthetic lethality 
observed with dual inactivation of VHL and CDK4/6. We generated Cas9-expressing 786-O 
cells that stably express both VHL and Tdtomato (hereafter referred to as VHL-Tdtomato) or 
GFP alone (EV-GFP) using bicistronic lentiviruses that did or did not contain a VHL cDNA, 
respectively (fig. S1A). We then mixed these cells 1:1, treated them with the CDK4/6 inhibitor 
palbociclib, and monitored the composition of the cell mixture by flow cytometry.  Notably, 
palbociclib inhibits ccRCC cell line growth at clinically achievable concentrations (13). 
Palbociclib decreased the number of the EV-GFP cells relative to the VHL-Tdtomato cells (Fig. 
3A), consistent with a synthetic lethal interaction between VHL loss and CDK4/6 inhibition. Such 
competition assays measure relative cellular fitness; a relative decrease in cell number, 
indicative of a relative decrease in cellular fitness, can reflect decreased cellular proliferation, 
viability, or both.   Similar results were achieved when the fluorophores were swapped such that 
the VHL cells expressed GFP and the EV cells expressed Tdtomato (fig. S1B). Notably, 
palbociclib did not score as a hit in our initial screen, probably because its differential effects on 
VHL-/- ccRCC cells compared to pVHL-proficient cells only manifested after 72 hours of 
treatment (data file S2 and Fig. 3A). 
In parallel, we treated EV-GFP and VHL-Tdtomato cells with palbociclib for 24 hours and 
measured changes in the phosphorylation of pRb, the canonical CDK4/6 substrate.  As 
measured by immunoreactivity with an antibody against phosphorylated pRb and by increased 
electrophoretic mobility of pRb, palbociclib noticeably reduced pRb phosphorylation in a dose-
dependent manner both in EV-GFP and (possibly more so) in VHL-Tdtomato cells (Fig. 3B). 
Unphosphorylated pRb represses the transcription factor E2F. In keeping with our 
immunoblot data, palbociclib decreased the expression of E2F-responsive mRNAs in both the 
EV-GFP and VHL-Tdtomato cells (fig. S1C). Moreover, palbociclib had similar effects on the 
transcriptome and on cell-cycle distribution in the VHL-/- 786-O cells compared to their pVHL-
restored counterparts (fig. S1D,E). Therefore, the differential sensitivity to CDK4/6 inhibition was 
not due to an inability of palbociclib to effectively inhibit CDK4/6 kinase activity in the pVHL-
proficient cells. Similar results were obtained in multiple other human VHL-/- ccRCC cell lines, 
including lines that are (A498) or are not (UMRC-2, 769-P) HIF2a-dependent (fig. S2A-F) 
(5,14,15). VHL expression in the absence of palbociclib had minimal effects on the fitness of the 
786-O, UMRC-2, and 769-P cells for the duration of the competition assays and conferred a 
fitness disadvantage to the A498 cells (fig. S3).   
To investigate whether the VHL-dependent effects of palbociclib on cellular fitness were 
on-target, we eliminated RB1 in 786-O cells using CRISPR/Cas9, infected them to stably 
express either VHL and Tdtomato (VHL-Tdtomato) or GFP alone (EV-GFP), and repeated our 
competition assays. In the absence of pRb, both the VHL-Tdtomato and EV-GFP expressing 
cells were similarly affect by palbociclib (Fig. 3C,D). In a complementary set of experiments, we 
introduced a palbociclib-resistant CDK6 variant (D104S) into 786-O cells (Fig. 3E,F). First, we 
confirmed that CDK6(D104S) attenuated the pharmacodynamic effects of palbociclib on the 
abundance of phosphorylated pRb relative to cells expressing wild-type CDK6 (Fig. 3F). The 
cells expressing CDK6(D104S) were then infected to stably express either VHL and Tdtomato 
(VHL-Tdtomato) or GFP alone (EV-GFP) and used in our competition assays. The presence of 
the D104S variant, like the loss of pRb, rendered the VHL-Tdtomato and EV-GFP equally 
sensitive to palbociclib (Fig. 3E). The structurally unrelated CDK4/6 inhibitor abemaciclib, like 
palbociclib, also preferentially reduced the fitness of EV-GFP cells relative to the VHL-Tdtomato 
cells (fig. S2G,H). Therefore, palbociclib’s effects in our assays were likely on-target.  
 
Loss of CDK4 or CDK6 individually is not sufficient for synthetic lethality with VHL inactivation 
In Drosophila cells, a single gene (cdk4) is the ancestral ortholog of both of the human 
genes CDK4 and CDK6, and the available CDK4/6 inhibitors, including palbociclib and 
abemaciclib, inhibit both paralogs. The observed rescue by CDK6(D104S) indicated that 
inhibition of CDK6 is necessary for the anti-fitness effects of palbociclib in VHL-/- ccRCC cells 
but did not address whether inhibition of CDK6 would also be sufficient for such effects. To 
address this, we created 786-O cells that stably express Cas9 and either VHL and Tdtomato 
(VHL-Tdtomato) or GFP alone (EV-GFP). We then mixed the cells (1:1), superinfected them 
either with a lentivirus encoding an sgRNA targeting CDK4 or CDK6 or with a lentivirus 
encoding a non-targeting control sgRNA (sgNT), and monitored the cell populations by flow 
cytometry (fig. S4, A and B). Although substantial knockdown was achieved (fig. S4C), loss of 
neither CDK4 nor CDK6 phenocopied the effects of the dual CDK4/6 inhibitors palbociclib and 
abemaciclib (fig. S4, A and B), suggesting that inhibition of both CDK4 and CDK6 is required (ie, 
that inhibition of either alone is not sufficient) to selectively suppress the fitness of VHL-/- ccRCC 
cells.  
 
The synthetic lethal relationship between CDK4/6 and VHL is not driven by HIF 
To begin to understand the basis of the synthetic lethal relationship between CDK4/6 
and VHL, we next created a pVHL variant in which the beta domain of pVHL, which is 
responsible for substrate recognition, is deleted (pVHLDB) (fig. S1a) and repeated our 786-O 
cell competition experiments using VHLDB -Tdtomato cells mixed with EV-GFP cells. In this 
experiment, we did not observe any difference in the ratio of VHLDB-Tdtomato : EV-GFP cells 
upon treatment with palbociclib (fig. S1f). These data suggest that pVHL’s ability to bind 
substrates through the beta domain decreases dependence on CDK4/6. 
The best documented substrate of pVHL is HIFa. HIF2a acts as an oncogenic driver in 
most ccRCC and many ccRCC cell lines, including 786-O cells, express HIF2a but not HIF1a 
(16,17). To investigate whether dysregulated HIF2a is necessary for the increased dependence 
of VHL-/- ccRCC lines on CDK4/6, we eliminated HIF2a in 786-O cells using CRISPR/Cas9 and 
then superinfected them with the lentiviruses expressing either VHL and Tdtomato (VHL-
Tdtomato) or GFP alone (EV-GFP) (Fig. 4A). We mixed these cell types (1:1), treated the mixed 
population with Palbociclib, and assessed the VHL-Tdtomato : EV-GFP ratio at multiple 
timepoints (Fig. 4B). Inhibition of CDK4/6 by palbociclib was synthetic lethal with VHL 
inactivation even in cells that lack HIF2a, demonstrating that HIF2a is not necessary for this 
interaction. 
 The binding of pVHL to HIF2a requires that HIF2a be prolyl-hydroxylated. In a 
complimentary set of experiments, we first treated the 786-O VHL-Tdtomato cells with 
increasing amounts of the prolyl hydroxylase inhibitor FG4592 and determined that 100 µM or 
more of FG4592 induced an increase in HIF2a abundance to an amount that was comparable 
to that in EV-GFP cells (Fig. 4C). We then repeated our competition assays with palbociclib in 
the presence or absence of 100 µM FG4592 and found that normalizing HIF2a abundance with 
FG4592 did not diminish the fitness disadvantage of the EV-GFP cells relative to the VHL-
Tdtomato cells (Fig. 4D). Collectively, these findings argue that HIF2a dysregulation is not 
necessary for the increased CDK4/6 requirement exhibited by VHL-/- ccRCC cells. 
 
Combined inhibition of CDK4/6 and HIF2a synergistically suppresses growth of HIF2a-sensitive 
VHL-defective ccRCC cell lines 
In ccRCC HIF2a transcriptionally induces the expression of cyclin D1, the binding 
partner for CDK4 and CDK6 (18-20). Because HIF2a activity was not necessary for the 
preferential inhibition of VHL-/- cell proliferation by palbociclib, we predicted that combining a 
HIF2a inhibitor with a CDK4/6 inhibitor would be additive or synergistic.  
To test this, we mixed VHL-Tdtomato and EV-GFP cells in a 1:1 ratio, treated them with 
palbociclib in the presence or absence of 2 µM PT2399, and measured the ratio of VHL-
Tdtomato : EV-GFP 10 days later (Fig. 5A-D). We observed a synergistic increase in the ratio of 
VHL-Tdtomato : EV-GFP cells that had been treated with both palbociclib and PT2399, as 
compared to cells treated with palbociclib alone in the HIF2a-dependent 786-O and A498 cell 
lines. Note that PT2399 monotherapy did not cause a statistically significant increase in the 
VHL-Tdtomato : EV-GFP ratio, consistent with earlier studies showing that 786-O cells tolerate 
the loss of HIF2a in short term cultures under high serum conditions (21,22). Palbociclib 
increased the abundance of cyclin D1 at both the mRNA and proteins levels, which was blunted 
by PT2399 in the HIF2a-dependent 786-O and A498 cell lines (Fig. 5E-H, fig. S5). As expected, 
PT2399 also decreased basal cyclin D1 mRNA and protein abundance in 786-O cells. However, 
for reasons that remain to be investigated, PT2399 had variable effects on basal cyclin D1 
mRNA and protein abundance in the A498 cells (Fig. 5F, fig. S5, and data in reference (5)). 
 In the HIF2a-independent UMRC-2 and 769-P cell lines, palbociclib again led to a loss 
of the EV-GFP cells, but now this loss was not enhanced further by PT2399, which correlated 
with a failure of PT2399 to downregulate cyclin D1 abundance (Fig. 5G,H, fig. S5). Therefore, 
and in keeping with our genetic experiments (Fig. 4B), PT2399 enhances palbociclib’s 
antifitness effects on HIF2a-dependent ccRCC cell lines and does not antagonize its effects on 
HIF2a-independent ccRCC lines. HIF2a-dependence was presumed on the basis of previous 
studies reporting the effect of PT2399 on soft agar and orthotopic tumor growth (5), soft agar 
growth after CRISPR/Cas9-mediated HIF2a elimination (5), and HIF2a (EPAS1) sgRNA guide 
depletion in Project Achilles (14,15).  
 
Palbociclib inhibits the growth of ccRCC orthotopic xenografts  
To begin to address the in vivo relevance of our findings, we orthotopically injected 786-
O (HIF2a-dependent) and UMRC-2 (HIF2a-independent) cells engineered to express firefly 
luciferase into nude mice. Two weeks later, we initiated weekly bioluminescent imaging (BLI). 
Mice exhibiting an increasing BLI signal for two successive weeks were then randomized to 65 
mg/kg palbociclib, 20 mg/kg PT2399, both, or vehicle(s) given daily by oral gavage for 28 days 
(the PT2399 arm was, however, omitted for the UMRC-2 cells as PT2399 monotherapy does 
not suppress the growth of these cells in such assays (5)). A submaximal dose of PT2399 was 
used to assess whether CDK4/6 inhibition would enhance or suppress its antitumor activity. The 
doses of palbociclib and PT2399 used did not result in any significant changes in body weight 
throughout the course of the study. Two mice from each treatment arm were euthanized after 2 
doses of therapy for pharmacodynamic studies. As expected, PT2399 decreased cyclin D1 
abundance and both agents, singly and in combination, decreased both phospho-pRb and Ki-67 
staining (fig. S6). 
Consistent with our cell culture studies, 786-O tumor growth was significantly retarded, 
as determined by BLI, after 28 days of treatment of palbociclib (Fig. 6A-C, fig. S7A,B). UMRC-2 
tumor growth was also significantly retarded in parallel experiments (Fig. 6D-F, fig. S8A,B). 
Similar results were obtained with mice implanted with 786-O xenografts and treated with 
abemaciclib (fig. S9). Similar doses of palbociclib and abemaciclib also suppressed the growth 
of subcutaneous tumors formed by a freshly explanted ccRCC (PDX model) (fig. S10). PT2399 
monotherapy, as expected, likewise suppressed 786-O cell tumor growth, with a trend toward 
greater suppression with the combination (Fig. 6B, fig. S7C,D). Abemaciclib’s ability to suppress 
786-O subcutaneous xenograft growth was recently reported by others (23). The combination 
did not suppress UMRC-2 cell tumor growth more effectively than palbociclib alone (Fig. 6E, fig. 
S8C). 
Following the completion of therapy, the mice were monitored by weekly BLI and 
euthanized when they appeared morbid, distressed, or lost >20% of their body weight. 
Palbociclib and PT2399 each individually prolonged the survival of the 786-O cell tumor bearing 
mice, with a trend toward enhanced survival in the combination treatment arm (Fig. 6C, fig. 
S7E-H). Three of the 11 mice treated with the combination therapy were alive and tumor-free 
(BLI-negative) 175 days after treatment ended. Palbociclib likewise enhanced the survival of the 
UMRC-2 bearing mice (Fig. 6F). Consistent with our cell culture studies, however, the activity of 
palbociclib in the UMRC-2 model was not enhanced by PT2399 (Fig. 6E,F, and fig. S8 D-F). 
 Discussion  
 
 We show that inactivation of the VHL tumor suppressor gene is synthetic lethal with loss 
of CDK4/6 activity. This relationship is robust because it can be detected in both Drosophila 
cells and a variety of human cancer cell lines and with both genetic CDK4/6 inhibitors and 
pharmacological CDK4/6 inhibitors. The antiproliferative effects of the pharmacological inhibitors 
were on-target because they were observed with two structurally distinct inhibitors and were 
rescued with a drug-resistant CDK6 point mutant or by eliminating pRb. The synthetic lethal 
relationship between VHL and CDK4/6 requires inactivation of both CDK4 and CDK6 and does 
not require HIF2a, which is a pVHL-regulated oncogenic driver in many ccRCCs. Accordingly, in 
VHL-defective cells that are HIF2a-dependent, combining a HIF2a inhibitor with a CDK4/6 
inhibitor synergistically suppresses their cellular fitness ex vivo.  In orthotopic tumor assays the 
HIF2a inhibitor and CDK4/6 inhibitor did not antagonize one another, suggesting they can be 
combined. As expected from our ex vivo studies, adding a HIF2a inhibitor did not enhance the 
activity of a CDK4/6 inhibitor against a HIF2a-resistant line and might have enhanced the 
activity of the CDK4/6 inhibitor against the HIF2a-sensitive line.  Further studies are needed to 
confirm the latter as well as to understand the molecular basis for the HIF2a-independent 
increase in CDK4/6-dependence of VHL-/- cells. 
Our findings are consistent with two earlier studies that showed that palbociclib and 
abemaciclib have antiproliferative effects against ccRCC cells at clinically-relevant 
concentrations, although these studies did not explore a genetic interaction between VHL and 
CDK4/6 (13,23). In a prior study we observed that VHL-/- ccRCCs were hypersensitive to a 
CDK6 shRNA compared to their VHL-proficient counterparts (12). We now suspect this earlier 
result was confounded by an shRNA off-target effect, because our new findings clearly show 
that CDK4 can compensate for CDK6 loss in VHL-/- ccRCC. 
Exploiting synthetic lethal relationships potentially addresses two vexing problems in 
cancer drug discovery: (i) how to pharmacologically tackle loss of function mutations and (ii) 
how to achieve a therapeutic window between normal cells and tumor cells. The clinical utility of 
the synthetic lethal paradigm has now been well established by the clinical activity of pol(ADP-
ribose)-polymerase (PARP) inhibitors in BRCA1/2-mutant breast and ovarian cancer (24-26). 
The VHL tumor suppressor gene is mutated in >90% of ccRCC cases (4), usually as the 
initiating or “truncal” event, and is thus an ideal target for the development of synthetic lethality-
based therapy that will selectively kill ccRCC cells. 
 In estrogen receptor-positive (ER)-positive breast cancer, ER drives transcription of the 
gene encoding cyclin D1, a requisite binding partner for both CDK4 and CDK6 (fig. S11). The 
combination of ER antagonists and CDK4/6 inhibitors is now standard of care in ER-positive 
breast cancer, presumably because both treatments converge on the activities of the cyclin 
D1/CDK4 and cyclin D1/CDK6 complexes. An analogy can be made to ccRCC, in which the 
VHL-regulated HIF2a transcription factor drives transcription of cyclin D1 (fig. S11). Moreover, 
as shown here, pVHL loss creates a hyperdependence on CDK4/6 that is not driven by HIF2a. 
Therefore, combining a HIF2a inhibitor with a CDK4/6 inhibitor should maximize the 
suppression of cyclin D1/CDK4 (or CDK6) activity while still leveraging the synthetic lethality 
between VHL and CDK4/6. Indeed, we observed synergistic suppression of cancer cell growth 
ex vivo when using a CDK4/6 inhibitor in combination with a HIF2a inhibitor in cell lines in which 
inhibition of HIF2a decreases cyclin D1. In cell lines where HIF2a inhibition did not alter cyclin 
D1 abundance, no synergy was observed (although these cell lines remained sensitive to 
CDK4/6 inhibitor monotherapy). In sum, our findings suggest that VHL status, like ER status, 
could be a predictive biomarker for CDK4/6 inhibitors. 
 In an effort to increase robustness we focused on genes that scored in both our 
Drosophila RNAi and human chemical screens. The use of Drosophila cells has several 
advantages. For example, many human paralogs are represented as a single gene in the 
Drosophila genome. Therefore false-negatives due to paralog compensation are less common 
in Drosophila RNAi screens than in typical human shRNA or sgRNA screens. Moreover, RNAi is 
highly efficient and titratable in Drosophila cells (27). Finally, genetic interactions that can be 
demonstrated in both Drosophila and human cells are likely to be hard-wired rather than highly 
context-dependent (28). However, a limitation of our study is that most of the genes we 
interrogated were not represented in both libraries and hence could not score as such. For 
example, MET scored in a previous shRNA screen (12) and in our chemical screen but was not 
represented in our Drosophila RNAi screen. c-Met inhibition might contribute to the clinical 
activity of the VEGFR inhibitor cabozantinib (29). Moreover, failure to score in Drosophila cells 
does not preclude a bona fide synthetic relationship in human ccRCC cells that could be clinical 
meaningful.  For example, MAP2K1 scored in a previous shRNA screen in human cells (12) and 
with two pharmacological inhibitors in our study, but not in Drosophila cells. MAP2K1, encoding 
MEK1, is intriguing because MEK1, via ERK, promotes CCND1 transcription and 
posttranslational assembly of active Cyclin D1/CDK4(or 6) complexes (30,31). Therefore, some 
of the other hits from our screens could be true positives worthy of further study.  
 Some, but not all, kidney cancer patients respond to HIF2a inhibitors, in keeping with the 
heterogenous HIF2a-dependence observed amongst VHL-/- ccRCC cell lines, and those 
patients that do respond eventually relapse. Combining drugs that have distinct mechanisms of 
action is the classical way to both increase efficacy and to decrease acquired and de novo 
resistance. These principles, together with our preclinical data to date, suggest that adding a 
CDK4/6 inhibitor to a HIF2a inhibitor would improve outcomes in ccRCC patients. 
 Spontaneous regression of ccRCCs are well described, which led to the idea that 
ccRCC is an immunogenic tumor (32,33). Moreover, immune checkpoint inhibitors are clearly 
active against this disease, despite the fact that ccRCCs have much lower mutational burdens 
compared to melanomas and mismatch repair-deficient colon cancers (34). Several studies 
have demonstrated that inhibiting CDK4/6 increases the immunogenicity of cancer cells and 
their removal by T cells (35-37). It is therefore possible that the antitumor effects we observed 
with CDK4/6 inhibitors would have been greater in immunocompetent hosts, including people. 
One can envision eventually combining a HIF2a inhibitor and a CDK4/6 inhibitor with the current 
frontline therapy of a checkpoint inhibitor and a VEGF inhibitor.  
 
Materials and Methods 
 
Cell lines and cell culture 
Drosophila melanogaster S2R+ cells were a kind gift from Dr. Norbert Perrimon’s 
laboratory (Harvard Medical School, Boston, MA). Human 786-O, 769-P, and A498 cells were 
originally obtained from American Type Culture Collection (ATCC). UMRC-2 cells were 
originally provided by Drs. Bert Zbar and Martson Linehan (National Cancer Institute, Bethesda, 
MD) (38). S2R+ cells were maintained in Schneider’s Drosophila Media (Life Technologies 
#21720024). 786-O, A498, and UMRC-2 cells were maintained in Dulbecco’s Modified Eagles 
Medium (DMEM) media (Life Technologies #11965126). 769-P cells were maintained in 
Roswell Park Memorial Institute (RPMI) media (Life Technologies #11875119). All media was 
supplemented with 10% fetal bovine serum (Life Technologies #10437028) and 1X Penicillin-
Streptomycin (Life Technologies #15140163). S2R+ cells were maintained at 25 °C and 
ambient CO2, and all human cells were maintained at 37 °C and 5% CO2. S2R+ cells were 
allowed to grow to confluency and were detached from culture plates by washing with spent 
media. All human cell lines were passaged at £80% confluency using 0.25% trypsin-EDTA (Life 
Technologies #25200114) to dissociate cells from culture flask. Cells were tested for 
mycoplasma at least every 8 weeks using the MycoAlertTM Mycoplasma Detection Kit (Lonza 
#LT07-418). 
Where indicated, the following chemicals were added to the media: palbociclib (1 mM 
stock in water, Selleckchem.com #S1116), abemaciclib (10 mM stock in dimethylsulfoxide 
(DMSO), a gift from Eli Lilly #LY2835219), FG-4592 (100 mM stock in DMSO, ApexBio 
Technology #ASP4187), PT2399 (10 mM stock in DMSO, a gift from Peloton Therapeutics 
#PT2399-16). All stock solutions were stored at -20 ˚C. 
 
 
sgRNA expression vectors for Drosophila cells 
The pl018 Drosophila expression vector (28) digested with BbsI (ThermoFisher Scientific 
#ER1011) for 30 minutes at 37 °C and the linearized backbone vector was purified by 
polymerase chain reaction (PCR) purification. sgRNA sequences were designed using the 
Drosophila RNAi Screening Core sgRNA design tool (www.flyrnai.org/crispr2/). Sense and anti-
sense vhl oligonucleotides containing appropriate overhangs for ligation into the BbsI-digested 
vector were synthetized by Integrated DNA Technologies (IDT) [vhl sense (5’-
GTTCGTCTGTACTGGGTGTGCGAGC-3’), vhl antisense (5’-
AAACGCTCGCACACCCAGTACAGAC-3’)]. 
An equimolar ratio of oligonucleotides (0.1 nanomoles of each sense and antisense 
oligonucleotide) were then annealed and phosphorylated by T4 Polynucleotide Kinase (New 
England BioLabs (NEB) #M0201). The annealing and phosphorylation were carried out using a 
30 minute incubation at 37 °C followed by a 5 minute incubation at 95°C. The incubation 
temperature was then lowered by 5°C/min until a final temperature of 25°C was reached. The 
annealed phosphorylated oligonucleotides were then ligated into the BbsI-digested pl018 by 
incubating for 5 minutes at room temperature with T7 Ligase (Enzymatics #L602L). A 2 µL 
aliquot of the ligation reaction was then transformed into chemically competent E. coli cells. 
Plasmid DNA from ampicillin-resistant colonies was evaluated by high resolution melt assay 
(HRMA) as previously described (21) and further confirmed by deep amplicon sequencing. 
 
dsRNA screening in Drosophila cells 
Screening and screen analysis were performed as previously described (39,40). 
Screening library plates were obtained from the Drosophila RNAi Screening Core (DRSC) 
(https://fgr.hms.harvard.edu). The DRSC FDA library (Drosophila orthologs of human genes 
encoding targets of FDA-approved drugs) was used for screening. 
 Lentiviral cDNA expression vectors 
The pLenti-EF1a-Cas9-FLAG-IRES-Neo vector (a kind gift from Dr. Samuel McBrayer 
(Kaelin Laboratory)) was used to generate Cas9-expressing cells. pLenti-EF1a-Cas9-FLAG-
IRES-Neo was created by PCR amplification of the cDNA from lentiCRISPR v2 (Addgene 
#52961) encoding Cas9 with a terminal Flag epitope tag with a 5’ primer that introduced an 
EcoRI restriction enzyme site and a 3’ primer that introduced a NotI restriction enzyme site. This 
PCR product was digested with EcoRI and NotI, gel-purified, and ligated to pLenti-EF1a-IRES-
Neo vector (a kind gift from Dr. Gang Lu (Kaelin Laboratory alumni)) that was restricted with 
these two enzymes. 
The pLX304-gate-IRES-GFP and pLX304-gate-IRES-Tdtomato destination vectors were 
made by Dr. Vidyasagar Koduri as previously described (41). The pDONR223-VHL, 
pDONR223-EV, and pDONR223-VHLDB entry clones were kind gifts from Dr. Abhishek 
Chakraborty (Kaelin Laboratory) and were used in Gateway cloning reactions to move the EV 
(empty vector) stuffer DNA insert into the pLX304-gate-IRES-GFP destination vector and to 
move the VHL and VHLDB (deletion of amino acids 91-121) cDNAs into the pLX304-gate-IRES-
GFP and pLX304-gate-IRES-Tdtomato destination vectors by homologous recombination using 
LR Clonase II (Life Technologies #11791100) at room temperature for 1 hour per the 
manufacturer’s instructions. A 3 µL aliquot of each recombination reaction was then transformed 
into 50 µL HB101 competent cells (Promega #L2011). Plasmids from Ampicillin-resistant 
colonies were isolated by QIAprep Spin Plasmid Miniprep Kit (Qiagen #27106) and validated by 
DNA sequencing. The EV insert is (5’-
TGTACAAAAAAGCAGGCTTTAAAGGAACCAATTCAGTCGACTGGATCCGGTACCGAATTCG
CGGCCGCACTCGAGATATCTAGACCCAGCTTTCTTGTA-3’). 
The pLenti-CDK6-D104S lentiviral vector was made by gateway cloning the pDONR223-
CDK6-D104S entry clone (a kind gift from Dr. Nicole Persky (Broad Institute)) into the pLenti-
EF1a-gate-3HA-PGK-Puromycin destination vector (a kind gift from Dr. Gang Lu (Kaelin 
Laboratory alumni)) as described above. 
The pLL3.7-EF1a-Fluc-Neo vector (a kind gift from Dr. Matthew Oser (Kaelin 
Laboratory)) was used to generate Fluc-expressing cells. pLL3.7-EF1a-Fluc-Neo was created 
by PCR amplification of the firefly luciferase cDNA from Luc.Cre empty vector (Addgene 
#20905) with a 5’ primer that introduced an XbaI restriction enzyme site and a 3’ primer that 
introduced a NotI restriction enzyme site. This PCR product was digested with XbaI and NotI, 
gel-purified, and ligated to a modified pLL3.7 lentiviral expression vector containing the EF1a 
promoter and a neomycin resistance gene (a kind gift from Dr. Samuel McBrayer (Kaelin 
Laboratory)) that was restricted with these two enzymes. 
 
Lentiviral sgRNA expression vectors 
The pLentiGuide-Puro vector (Addgene #52963) was used as a backbone for all sgRNA 
expression vectors with the exception of the sgRB1 expression vector, which was made with the 
lentiCRISPRv2-zeo vector (a kind gift from Dr. Samuel McBrayer (Kaelin Laboratory)). The 
lentiCRISPRv2-zeo vector was created by PCR amplification of a cDNA encoding the zeocin 
resistance gene from the pLenti4/V5-DEST vector (Invitrogen #V49810) using primers that 
introduced 5’ and 3’ homology arms targeted to regions of the lentiCRISPR v2 vector (Addgene 
#52961) flanking the puromycin resistance gene cDNA. Primers corresponding to these 
homology arms were used in an inverse PCR reaction with the lentiCRISPR v2 vector as a 
template. The zeocin resistance gene cDNA was gel-purified and used in an InFusion exchange 
reaction with the inverse PCR product. 
pLentiGuide-Puro or lentiCRISPRv2-zeo vectors were digested with BsmBI (NEB 
#R0580) or FastDigest Esp3I (Life Technologies #FD0454) for 30 minutes at 37 °C and the 
resulting linearized vectors were gel-purified. sgRNA oligonucleotide sequences were designed 
using the Broad Institute Genetic Perturbation Platform (GPP) Web Portal  
(https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design) with corresponding 
BsmBI/Esp3I overhangs added to facilitate ligation. Oligonucleotides were synthesized by IDT. 
Oligonucleotides were annealed using 0.15 nanomoles of each sense and antisense 
oligonucleotides. The oligonucleotides were heated at 95 °C for 4 minutes and allowed to slowly 
cool to room temperature. Annealed oligonucleotides were then diluted 1:100 in nuclease-free 
water and ligated into the linearized vectors using T4 ligase in a 4-hour incubation at room 
temperature. A 2 µL aliquot of the ligation mixture was then transformed into 25 µL HB101 
chemically competent E. coli cells (Promega #L2011). Plasmids from Ampicillin-resistant 
colonies were isolated by QIAprep Spin Plasmid Miniprep Kit (Qiagen #27106) and validated by 
DNA sequencing. The sgRNA oligonucleotides used for editing (including BsmBI/Esp3I 
overhangs) are listed in table S1. 
 
Lentivirus production 
Lentiviruses were made by Lipofectamine 2000 (Life Technologies #13778150)-based 
cotransfection of HEK293T cells with the lentiviral expression vector and the packaging vectors 
psPAX2 (Addgene #12260) and pMD2.G (Addgene #12259) in a 4:3:1 ratio. Supernatant was 
replaced after 24 hours, and virus-containing supernatant was collected after 48 and 72 hours. 
Virus-containing supernatant was then pooled, purified using a 45 µm filter, and frozen at -80 °C 
in 500 µL aliquots. 
 
Lentiviral infection 
Cells were seeded into 6-well plates at a density of 300,000 cells/well and allowed to 
attach for at least 6 hours. Spent media was discarded and replaced with 2.5 mL fresh media, 
500 µL lentivirus, and Polybrene (Santa Cruz Biotechnology #SC-134220) at a final 
concentration 8 µg/mL (except when infecting UMRC-2 cells, when Polybrene was omitted). 
Plates were centrifuged at 4000 ´ g for 30 minutes at 25 °C, then incubated for 14-16 hours at 
37 °C. The supernatant was then removed and replaced with fresh media for 12-24 hours prior 
to the addition of selection antibiotics. Lentivirally infected 786-O cells were selected for in 
media containing 10 µg/mL blasticidin, 600 µg/mL G418, 2 µg/mL puromycin, or 100 µg/mL 
zeocin as appropriate for the lentiviral drug resistance cassette. Lentivirally infected UMRC-2 
cells were selected for in media containing 10 µg/mL blasticidin or 1.8 mg/mL G418 as 
appropriate for the lentiviral drug resistance cassette. Lentivirally infected 769-P and A498 cells 
were selected in media containing 10 µg/mL blasticidin. 
 
Immunoblot analysis 
Cells grown in 6 cm or 10 cm tissue culture dishes were washed once with 1X 
phosphate buffered saline (PBS). A cell lifter was then used to detach the cells in 1 mL fresh 1X 
PBS. The cell suspension was transferred to a 1.5 mL microcentrifuge tube and centrifuged for 
250 ´ g for 3 minutes. The supernatant was aspirated and the cell pellet was lysed by 
incubation in 50-100 µL EBC lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40) 
containing protease inhibitor cocktail (cOmplete, Roche Applied Science #11836153001) and 
phosphatase inhibitors (PhosSTOP, Sigma #04906837001) for 30 minutes with gentle rotation 
at 4 °C. The lysates were then clarified by centrifugation at 17,000 ´ g for 10 minutes at 4 °C. 
Whole cell extracts were quantified using a BCA Protein Assay (ThermoFisher Scientific 
#PI23227). Extracts were boiled for 5 minutes in sample buffer (3X: 6.7% sodium dodecyl 
sulfate (SDS), 33% glycerol, 300 mM DTT, Bromophenol Blue). Protein concentrations were 
standardized using 1X sample buffer and samples were resolved by SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes using a TransBlot 
Turbo (Bio-Rad #1704155). Membranes were blocked by incubation in 5% milk/TBS/0.1% 
Tween-20 for 1 hour at room temperature, washed 3 times with TBS/0.1% Tween-20 (TBS-T) (5 
minutes per wash), and then probed with primary antibody as indicated for 1 hour (with the 
exception of HIF2a, which was probed for overnight). Membranes were washed 3 times in TBS-
T (5 minutes per wash) and then incubated with 1:5000 horseradish peroxidase (HRP)-
conjugated secondary antibody in 5% milk/TBS-T (goat anti-mouse IgG (ThermoFisher #31430) 
or goat anti-rabbit IgG (ThermoFisher #31460)) for 1 hour at room temperature. Membranes 
were washed 3 times in TBS-T (5 minutes per wash). Bound antibodies were then detected with 
enhanced chemiluminescence western blotting reagents (ThermoFisher Scientific 
#WBKLS0500) or SuperSignal West Pico (ThermoFisher Scientific #PI34078). 
The primary antibodies used were: rabbit a-VHL (Cell Signaling #68547, used at 1:500), 
rabbit a-HIF2a (Bethyl #118-1261, used at 1:1000), mouse a-Vinculin (Sigma #V9131, used at 
1:10000), rabbit a-Actin (Cell Signaling #4970, used at 1:2000), rabbit a-Tubulin (Cell Signaling 
#2146, used at 1:1000), rabbit a-CDK4 (Cell Signaling #12790, used at 1:1000), rabbit a-CDK6 
(Cell Signaling #13331, used at 1:1000), rabbit a-Phospho-pRb (Ser780) (Cell Signaling #8180, 
used at 1:5000), a-Phospho-pRb (Ser795) (Cell Signaling #9301, used at 1:5000), a-Phospho-
pRb (Ser608) (Cell Signaling #8147, used at 1:5000), a-Phospho-pRb (Ser807/811) (Cell Signaling 
#8516, used at 1:5000), mouse a-pRb (Cell Signaling #9309, used at 1:5000), rabbit a-NDRG1 
(Cell Signaling #5196, used at 1:750), rabbit a-Cyclin D1 (Cell Signaling #2978, used at 1:500). 
 
Small-molecule screening in human cells 
Small-molecule screening was performed using the ICCB-Longwood Screening Facility 
(https://iccb.med.harvard.edu). GFP-expressing cells were seeded into black-sided 384-well 
plates at 600 cells/well using a Multidrop Combi Reagent Dispenser (Thermo Fisher Scientific 
#5840300) in a final volume of 30 µL/well. After 24 hours, a Seiko Compound Transfer Robot 
was used to pin transfer 100 nL of each library plate well into the cell-containing plates. 48 
hours later the GFP signal was measured as a proxy for cell number using an Acumen Laser 
Scanning Cytometer. The Ludwig Anti-Cancer Library of compounds was a kind gift from Dr. 
Joan Brugge (Harvard Medical School, Boston, MA). It contains ~400 compounds in 10-point 
concentration curves ranging from 1 nM – 20 µM. The average Z’ value for this screening setup 
was 0.75 when using Actinomycin D as the positive control. 
 
GFP reporter assay for Cas9 activity 
786-O cells infected with a pLenti-EF1a-Cas9-P2A-neo lentivirus were superinfected 
with a lentivirus expressing GFP and an sgRNA that targets GFP (pXPR_011, Addgene 
#59702). Superinfected cells were selected for puromycin resistance and tested for GFP 
fluorescence by flow cytometry at multiple timepoints. 786-O cells lacking Cas9 and mock 
infected cells (that were not puromycin selected) were uses as positive and negative controls, 
respectively, for GFP expression. Loss of GFP fluorescence over time in the superinfected cells 
was used to monitor CRISPR/Cas9-based editing of GFP. 
 
Pharmacodynamic studies of Palbociclib, Abemaciclib, FG4592, and PT2399 
Cells were seeded at 300,000 cells/10 cm dish and treated with the indicated 
concentrations of the specified drug for 24 hours (except in the case of PT2399, which was 
incubated for 48 hours). Cells were then collected and immunoblot analysis of 
pharmacodynamic marker proteins was performed as described above. 
 
Flow cytometry-based direct competition assay 
Cells were infected with a pLX304-EV-IRES-GFP (EV-GFP), pLX304-VHL-IRES-
Tdtomato (VHL-Tdtomato), or pLX304-VHLDB-IRES-Tdtomato (VHLDB-Tdtomato) lentivirus as 
indicated, followed by selection for antibiotic resistance with 10 µg/mL Blasticidin. For 
competition assays with small molecule inhibitors, EV-GFP and VHL-Tdtomato (or VHLDB -
Tdtomato) were mixed 1:1 and seeded at 300,000 cells/10 cm dish and treated with the 
indicated concentrations of drug or the equivalent volume of vehicle. The cells were split every 
3-4 days. After each split a portion of the cells were reseeded in fresh media and drug and the 
remaining cells were used for flow cytometry analysis. 
For competition assays using CRISPR/Cas9 editing of target genes, EV-GFP and VHL-
Tdtomato cells were mixed 1:1 and seeded at 300,000 cells/well in a 6-well dish and allowed to 
attach for at least 6 hours. The cells were then infected with viruses encoding sgRNAs against 
the desired target as described above. After each split a portion of the cells were reseeded in 
fresh media and drug and the remaining cells were used for flow cytometry analysis. 
For flow cytometry 10,000 cells per sample were analyzed using a BD-Fortessa flow 
cytometer with the BD FACSDIVA software. Living single cells were gated, then the 
percentages of those cells that were GFP-positive or Td-tomato positive were quantified. The 
ratio of Tdtomato-positive:GFP-positive cells was used as a measure of VHL+/+:VHL-/- cells, and 
was normalized to the ratio in the vehicle-treated or non-targeting sgRNA sample for each 
timepoint. 
 
RT-qPCR 
Cells were homogenized using QIAshredder columns (QIAGEN #79654) and total RNA 
was extracted using the RNeasy Mini Kit (QIAGEN #74106) according to manufacturer’s 
instructions. cDNA was reverse transcribed from purified RNA using the AffinityScript qPCR 
cDNA Synthesis Kit (Aglient #600559) according to manufacturer’s instructions. Real-time PCR 
was performed in duplicate for each primer pair on each sample using LightCycler 480 SYBR 
Green I Master Mix (Roche Diagnostics #04707516001) using half the volume of each reagent 
specified in manufacturer’s instructions. Ct values were analyzed using the 2-DDCt method using 
actin 5c for reference in Drosophila cells and Beta-Actin (ACTB) for reference in human cells. 
The PCR primers used are listed in table S2. 
 
Cell Cycle Distribution Analysis 
Cells were plated at ~30% confluency and treated with 0, 200, or 400 nM Palbociclib for 
24 hours. During the final 45 minutes of treatment, culture medium was supplemented with 10 
µM BrdU. At the completion of treatment, cells were trypsinized. Once the cells had detached 
from the tissue culture plate the trypsin was neutralized with complete media and the cells were 
counted using a Vi-CELL XR (Beckman Coulter). One million cells were pelleted and the 
supernatant was aspirated. Cells were then washed once with 1X PBS and pelleted. Cells were 
fixed, stained, and analyzed by flow cytometry using the FITC BrdU Flow Kit (BD Pharmingen 
#BD559619) according to the manufacturer’s instructions. Histograms were created using 
Flowjo. 
 
RNA Sequencing 
786-O EV-GFP and 786-O VHL-Tdtomato cells were treated with 400 nM Palbociclib or 
vehicle for 72 hours and then washed once with 1X PBS. A cell lifter was then used to detach 
the cells in 1 mL fresh 1X PBS. Cells were pelleted and supernatant was aspirated. Total RNA 
was isolated as described for RT-qPCR. 
Libraries were prepared using Roche Kapa mRNA HyperPrep sample preparation kits 
from 100ng of purified total RNA according to the manufacturer’s protocol. The finished dsDNA 
libraries were quantified by Qubit fluorometer, Agilent TapeStation 2200, and RT-qPCR using 
the Kapa Biosystems library quantification kit according to manufacturer’s protocols. Uniquely 
indexed libraries were pooled in equimolar ratios and sequenced on two Illumina NextSeq500 
runs with single-end 75bp reads by the Dana-Farber Cancer Institute Molecular Biology Core 
Facilities. 
Sequenced reads were aligned to the UCSC hg38 reference genome assembly and 
gene counts were quantified using STAR (v2.5.1b) (42). Differential gene expression testing 
was performed by DESeq2 (v1.10.1) (43) and normalized read counts (FPKM) were calculated 
using cufflinks (v2.2.1) (44). RNAseq analysis was performed using the VIPER snakemake 
pipeline (45). 
 
ccRCC cell line orthotopic xenografts 
Adherent Fluc-expressing cells grown in 15 cm tissue culture dishes were detached with 
trypsin, resuspended in DMEM with 10% FBS, and centrifuged at 300 x g for 3 minutes.  The 
cell pellets were then washed once with 1X PBS. The cells were resuspended in 1X PBS 
containing 2% FBS. Cell number and viability was assessed by automated cell counting on a Vi-
CELL XR (Beckman Coulter). 1X PBS containing 2% FBS was then added to achieve a cell 
concentration of 108/ml. 
Female NCr nude mice at ~8 weeks old (Taconic #NCRNU-F) were anesthetized by 
intraperitoneal injection of ketamine/xylazine. An incision was made in the skin and 2 ´ 106 
viable cells (20 µL) were injected through the fascia and into the lower pole of the renal 
parenchyma. The incision was closed using 2-3 wound clips. The mice were subcutaneously 
administered buprenorphine for analgesia immediately following wound closure and were 
allowed to regain movement and consciousness on a slide warmer. After surgery, the viability of 
the remaining uninjected cells was again assessed by counting on a Vi-CELL XR and was 
confirmed to be >98%. Mice were monitored daily for changes in weight, changes in activity, 
and food and water intake. Baytril was administered in drinking water for 7 days after surgery to 
prevent infection. Wound clips were removed 7-8 days after surgery.  
Tumors were monitored weekly by bioluminescent imaging (BLI) beginning 2 weeks after 
surgery (see below). Once the tumors showed at least 2 consecutive weeks of growth, the mice 
were randomized to receive Abemaciclib (60 mg/kg), Palbociclib (65 mg/kg) PT2399 (20 mg/kg), 
the combination of Palbociclib (65 mg/kg) and PT2399 (20 mg/kg), or the corresponding 
vehicle(s), all by oral gavage daily for 28 days. The monotherapy mice received also received 
the vehicle for the complementary drug used in the combination arm, and control mice received 
the vehicles for both combination partners. Imaging was performed by Animal Resources staff 
who were blinded to the treatment groups. Formulations were as follows: Abemaciclib was 
prepared in 1% hydroxyethyl cellulose/25 mM phosphate buffer, Palbociclib was prepared in 50 
mM sodium lactate buffer pH 4.0, PT2399 was dissolved in 10% ethanol/30% polyethylene 
glycol (PEG)400/60% water containing 0.5% methylcellulose and 0.5% Tween80. Photon 
emission was normalized to the photon count on Day 0 (the time of enrollment). Mice were 
sacrificed at the end of the dosing period for studies in which tumor weight was measured. For 
survival analysis studies the mice were sacrificed when they lost 20% of their body weight or 
when they appeared moribund or distressed. 
 
Bioluminescent imaging 
Mice were administered 15 mg/kg luciferin by intraperitoneal injection and anesthetized 
using isoflurane. Imaging began 10 minutes after luciferin was injected and was carried out 
using an IVIS camera (PerkinElmer). Bioluminescence images were analyzed using Living 
Image version 4.2 software (PerkinElmer). 
 
Histology and immunohistochemistry analysis of ccRCC cell line xenografts 
Tumor-bearing kidneys were harvested and immediately fixed with 10% formalin in PBS 
for 24 hours. Tissue was then washed and stored in 70% ethanol prior to being embedded in 
paraffin and sectioned to 4 µM thickness. Sections were baked for 30 minutes at 60 °C to melt 
excess paraffin. Sections were stained with hematoxylin and eosin. Immunohistochemistry 
staining for anti-Cyclin D1 (Neomarkers #RM-9104), anti-Ki-67 (BioCare #CRM325), and 
phospho-Ser807/811-pRb (Cell Signaling #9308) was performed on a Bond III (Leica 
Biosystems) with the Bond Polymer Refine Detection Kit (Leica Biosystems #DS9800). Antigen 
retrieval was performed using Bond Epitope Retrieval Solution 2 for 20 minutes (Cyclin D1 and 
Ki-67) or Epitope Retrieval Solution 1 for 30 minutes (phospho-Ser807/811-pRb). Sections were 
incubated for 30 minutes with primary antibody diluted in Bond Primary Antibody Diluent 
followed by incubation for 10 minutes with HRP-conjugated secondary antibody. Sections were 
then incubated for 5 minutes with chromogen 3,3’-diaminobenzidine to visualize staining. 
Sections were counterstained with hematoxylin and dehydrated in graded ethanol and xylene. 
Slides were digitized using a ScanScope XT (Leica Biosystems) and representative images 
were obtained using the Indica Lab Halo platform. 
 
Quantification and statistical analysis 
Method of statistical analysis is indicated in the figure legend for individual experiments. 
Analyses were performed using Graphpad Prism 7 software (Graphpad). For comparison of two 
groups, t-test with Welch’s correction for unequal variance was used. For comparison of multiple 
groups with one variable, one-way ANOVA was used with Dunnett’s post-hoc testing for multiple 
comparisons. For comparison of multiple groups with more than one variable, two-way ANOVA 
was used with Dunnett’s (when comparing groups to a control group) or Tukey’s (when 
comparing groups to all other groups) post-hoc testing for multiple comparisons. Differences 
were considered statistically significant if the p-value was <0.05. For all figures, * indicates p-
value <0.05, ** indicates p-value <0.01, *** indicates p-value <0.001, and **** indicates p-value 
<0.0001. Error bars represent + SD for bar graphs, ± SD for scatter plots. 
 
Mouse PDX xenograft model 
 The study was performed by Champions Oncology, Inc.. Tumor fragments harvested 
from donor animals at passage 11 were implanted in the flank region of female Athymic Nude-
Foxn1nu mice (Envigo) between 7-9 weeks of age. Tumor size and body weight were measured 
twice weekly. Palbociclib (75 mg/kg) was dosed daily and Abemaciclib (60 mg/kg) was dosed 
twice daily for 25 days. All mice were dosed with 10 mL/kg by oral gavage. 
 
Supplementary Materials 
Fig S1. Control experiments for competition experiments done with isogenic ccRCC cell lines 
treated with CDK4/6 inhibitors. 
Fig S2. The CDK4/6 inhibitor palbociclib preferentially inhibits pVHL-deficient cells in various 
ccRCC cell lines. 
Fig S3. Changes in proliferation of ccRCC cells after pVHL reconstitution does not account for 
differential sensitivity to CDK4/6 inhibition. 
Fig S4. Individual knockdown of CDK4 or CDK6 does not differentially affect viability of ccRCC 
cells based on VHL status. 
Fig S5. PT2399 attenuates palbociclib-induced upregulation of cyclin D1 abundance in HIF2a-
dependent, but not HIF2a-independent, cell lines. 
Fig S6. Effect of palbociclib, PT2399, and their combination on cyclin D1 and phospho-pRb 
abundance in vivo. 
Fig S7. Growth of ccRCC orthotopic xenografts during treatment with vehicle, palbociclib, 
PT2399, or their combination. 
Fig S8. Growth of HIF2a inhibition-resistant VHL-null ccRCC orthotopic xenografts during 
treatment with vehicle, palbociclib, or the combination of palbociclib with PT2399. 
Fig S9. Antitumor activity of abemaciclib in VHL-null ccRCC orthotopic xenografts. 
Fig S10. Antitumor activity of palbociclib and abemaciclib in a ccRCC PDX model. 
Fig S11. Schematic of analogous signaling mechanisms in breast cancer and ccRCC. 
Table S1: sgRNA oligonucleotides. 
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Data file S1: Results of screen for synthetic lethality with vhl inactivation using dsRNA library in 
Drosophila cells. 
Data file S2: Results of screen for synthetic lethality with VHL inactivation using chemical library 
in human 786-O and UMRC-2 ccRCC cells. 
Data file S3: Overlap between genes encoding targets of chemicals that scored in chemical 
screen and human orthologs of Drosophila genes that scored in dsRNA screen. 
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Figure legends:  
 
Fig 1. RNAi screen for genes that are synthetically lethal with vhl inactivation in 
Drosophila S2R+ cells. (A) Relative mRNA expression for sima, the Drosophila melanogaster 
ortholog of the human gene encoding HIFa, and the indicated sima-responsive genes in vhl-null 
S2R+ cells as compared to wild-type S2R+ cells. Data are mean ± SD of n=2 independent 
experiments. (B) Z-scores for change in viable cell number, as determined by CellTiter-Glo 
assays, after a 5-day incubation with dsRNAs (3 dsRNAs per gene on average, 448 genes) in 
vhl-null S2R+ (x-axis) and WT S2R+ (y-axis) cells. Each dot represents the median Z-score 
(n=3 biological replicates) for one dsRNA. dsRNAs targeting the pan-essential Drosophila gene 
thread are indicated in red; those targeting cdk4 are indicated in blue. (C) Quantification of 
select data in (B). LacZ and GFP dsRNAs are negative controls that do not affect cell viability. 
Data are mean ± SD of n=3 independent experiments. (D) Top hits from (B), based on the top 
scoring dsRNAs for each gene. A hit was defined as a gene targeted by a dsRNA with Z<-1.5 in 
at least 2/3 of replicates in EV cells and not more than 1/3 of VHL cells. 
 
 
Fig 2. Small-molecule screen for chemicals that are synthetically lethal with VHL 
inactivation in ccRCC cell lines. (A) Immunoblot of HIF2α, VHL, and vinculin (loading control) 
abundance in parental VHL-/- 786-O and UMRC-2 cells and those stably infected with lentivirus 
expressing GFP and VHL (VHL) or GFP alone (EV), as indicated. Blots are representative of 3 
biological replicates. (B) Z-scores assessing the change in viable cell number, as determined by 
a CellTiter-Glo assay, after a 48-hour incubation with DMSO, epothilone B (123 µM), AT7519 
(370 µM), or flavopiridol (41 µM) in the indicated cell lines. Data are mean ± SD of n=2 
independent experiments. (C) Top scoring drugs based on differential Z scores (VHL - EV) in 
786-O and UMRC-2 cells, and their putative protein targets. Yellow highlighting indicates targets 
that were interrogated in the Drosophila dsRNA screen (Fig. 1) but were not hits in that screen. 
Green highlighting indicates the targets human CDK4/6 (ortholog cdk4), and to a lesser extent 
CDK2 (ortholog cdk2), that were hits in the Drosophila dsRNA screen. (D) Venn diagram 
showing overlap of the human orthologs of the Drosophila dsRNA screening library and the 
genes encoding the protein targets of the ccRCC drug screen library. Shaded regions indicate 
screen hits. The data behind this diagram is in data files 1-3. 
 
 
Fig 3. The CDK4/6 Inhibitor palbociclib preferentially inhibits pVHL-deficient ccRCC cells 
in an on-target manner. (A) Ratio of 786-O cells stably infected with a bicistronic lentivirus 
expressing VHL and Tdtomato (VHL-Tdtomato) to 786-O cells infected with GFP alone (EV-
GFP) that had been mixed 1:1 and then treated with 0, 200, or 400 nM palbociclib for 3 to 10 
days. Data are mean ± SD of n=4 independent experiments. *P<0.05, **P<0.01, ***P<0.001, 
and ****P<0.0001 by two-way ANOVA. (B) Immunoblot of total and Ser780-, Ser608-, Ser795-, and 
Ser807/811-phosphorylated pRb in 786-O cells expressing VHL-Tdtomato or EV-GFP and treated 
with 100, 200, 400, or 800 nM palbociclib, as indicated by the triangle, for 24 hours. Blots are 
representative of 3 biological replicates. (C) 786-O cells that underwent CRISPR/Cas9 editing 
with an RB1 sgRNA (as indicated, +) and then were infected, mixed, and treated as in (A). 
Shown is the ratio of RB1 null VHL-Tdtomato cells to RB1 null EV-GFP cells after treatment. 
Data are mean ± SD of n=3 independent experiments. (D) Immunoblot of Rb, VHL, and actin 
(loading control) abundance in 786-O cells edited and infected as described in (C), but not 
otherwise treated. Blots are representative of 3 biological replicates. (E) Ratio of 786-O cells 
stably infected with a lentivirus expressing CDK6(D104S) and either VHL-Tdtomato cells to 
those infected with CDK6(D104S) and EV-GFP that had been mixed and treated as described 
in (A). Data are mean ± SD of n=3 experiments. (F) Immunoblot of 786-O cells stably infected 
with lentivirus expressing either wild-type (WT) or mutant (D104S) CDK6 and then treated with 
50, 100, 200, 400, 800 nM, or 1600 nM palbociclib, as indicated by the triangle, for 24 hours. 
Blots are representative of 3 biological replicates. 
 
 
Fig 4. Increased HIF2a is neither necessary nor sufficient for the synthetic lethal 
relationship between CDK4/6 and VHL in ccRCC. (A) Immunoblot of HIF2α, VHL, cyclin D1, 
and vinculin (loading control) abundance in 786-O cells that underwent CRISPR/Cas9 editing 
with a HIF2a sgRNA (as indicated, +) and were then infected to express VHL and Tdtomato 
(VHL-Tdtomato) or GFP alone (EV-GFP). Blots are representative of 3 biological replicates. (B) 
Ratio of HIF2a null VHL-Tdtomato cells to HIF2a null EV-GFP cells that were mixed 1:1 and 
then treated with 0, 200, or 400 nM palbociclib for 4 to 10 days. Data are mean ± SD of n=3 
independent experiments. **P<0.01 and ****P<0.0001 by two-way ANOVA. (C) Immunoblot of 
HIF2α and actin (loading control) abundance in 786-O cells stably expressing VHL and 
Tdtomato (VHL-Tdtomato) or GFP alone (EV-GFP) and treated with vehicle (0) or 25, 50, 100, 
or 200 µM FG4592 for 36 hours. Blots are representative of 3 biological replicates. (D) Ratio of 
VHL-Tdtomato cells to EV-GFP 786-O cells that were mixed 1:1 and then treated with 0, 200, or 
400 nM palbociclib with or without 100 µM FG4592 for 10 days. Data are mean ± SD of n=3 
independent experiments. 
 
 
Fig 5. Palbociclib and PT2399 synergistically suppress cell viability of VHL-null cells in 
PT2399-sensitive, but not PT2399-insensitive, ccRCC cell lines. (A) Ratio of VHL-Tdtomato-
expressing to EV-GFP-expressing 786-O cells that were mixed 1:1 and then treated with 0, 200, 
or 400 nM palbociclib with or without 2 µM PT2399 for 10 days. Data are mean ± SD of n=3 
independent experiments. (B-D) As described for (A) in A498 (B), UMRC-2 (C), and 769-P (D) 
cells. (E) Relative mRNA expression for CCND1 in EV-GFP-expressing 786-O cells treated with 
with 2 µM PT2399, 400 nM palbociclib, or the combination (as indicated) for 48 hours. Data are 
mean ± SD of n=2 independent experiments.   (F-G) As described for (E) in A498 (F), UMRC-2 
(G), and 769-P (H) cells. **P<0.01, ***P<0.001, and ****P<0.0001 by two-way ANOVA. 
 
 
Fig 6. In vivo antitumor activity of palbociclib in VHL-null ccRCC. (A) Representative 
bioluminescent images (BLI) of orthotopic tumors formed by firefly luciferase-expressing 786-O 
cells before and after mice were treated with vehicle or 65 mg/kg palbociclib, dosed daily for 28 
days by oral gavage. Images are representative of n=10 or 9 mice, respectively. (B) 
Quantification of BLI at day 28 in mice described in (A) and in those treated daily by oral gavage 
with 20 mg/kg PT2399 or both 20 mg/kg PT2399 and 65 mg/kg palbociclib (combo). Data are 
mean ± SD overlaying the individual data points from n=10, 9, 11, and 11, respectively. Photon 
counts on day 28 were normalized to those on day 0 for each mouse individually. ****P<0.0001 
by one-way ANOVA.  (C) Kaplan-Meier survival curves for mice described in (B). “Rx” bar 
indicates duration of treatment. Log-rank (Mantel-Cox) test p<0.0001, log-rank test for trend 
p=0.0001. (D to F) As described in (A to C) using UMRC-2 cells. n=11 mice (vehicle), 8 
(palbociclib), and 6 (combo). *P<0.05 (P=0.0112) by one-way ANOVA (F); P=0.0012 by log-
rank Mantel-Cox test (F), in which log-rank test for trend showed P>0.05. 
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